Mast cell phenotype, TNFα expression and degranulation status in non-small cell lung cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Shikotra, A ^a   Ohri, C M ^b   Green, R H ^b   Waller, D A ^b   Bradding, P ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMASE; TRYPTASE; TUMOR NECROSIS FACTOR;

AGED; CELL MOTION; CYTOTOXICITY; DEGRANULATION; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; LUNG TUMOR; MALE; MAST CELL; MIDDLE AGED; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PHENOTYPE; SURVIVAL ANALYSIS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL DEGRANULATION; CELL MOVEMENT; CHYMASES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MALE; MAST CELLS; MIDDLE AGED; PHENOTYPE; SURVIVAL ANALYSIS; TRYPTASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85002636980     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep38352     Document Type: Article

References (42)

1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J Cancer 136, E359-E386 (2015).
2. Galdiero, M. R., Varricchi, G., Marone, G. The immune network in thyroid cancer. Oncoimmunology. 5, e1168556 (2016).
3. Orozco-Morales, M., Soca-Chafre, G., Barrios-Bernal, P., Hernandez-Pedro, N., Arrieta, O. Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer. Mediators. Inflamm. 2016, 3494608 (2016).
4. Hanahan, D., Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322 (2012).
5. Bradding, P., Arthur, G. Mast cells in asthma-state of the art. Clin Exp. Allergy 46, 194-263 (2016).
6. Marichal, T., Tsai, M., Galli, S. J. Mast cells: potential positive and negative roles in tumor biology. Cancer Immunol Res. 1, 269-279 (2013).
7. Takanami, I., Takeuchi, K., Naruke, M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 88, 2686-2692 (2000).
8. Imada, A., Shijubo, N., Kojima, H., Abe, S. Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur. Respir. J. 15, 1087-1093 (2000).
9. Nagata, M. et al. Chymase-positive mast cells in small sized adenocarcinoma of the lung. Virchows Archiv 443, 565-573 (2003).
10. Galinsky, D. S., Nechushtan, H. Mast cells and cancer-no longer just basic science. Crit Rev Oncol. Hematol. 68, 115-130 (2008).
11. Coussens, L. M. et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13, 1382-1397 (1999).
12. Rudolph, M. I. et al. The influence of mast cell mediators on migration of SW756 cervical carcinoma cells. J Pharmacol Sci. 106, 208-218 (2008).
13. Cianchi, F. et al. The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin Cancer Res. 11, 6807-6815 (2005).
14. Bradding, P., Holgate, S. T. Immunopathology and human mast cell cytokines. Crit. Rev. Oncol. Haematol. 31, 119-133 (1999).
15. Tataroglu, C., Kargi, A., Ozkal, S., Esrefoglu, N., Akkoclu, A. Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumor stage in non-small cell lung carcinomas (NSCLC). Lung Cancer 43, 47-54 (2004).
16. Dundar, E. et al. The significance and relationship between mast cells and tumour angiogenesis in non-small cell lung carcinoma. J Int. Med Res. 36, 88-95 (2008).
17. Welsh, G. et al. Macrophage and mast cell invasion of tumour cell islets confers a marked survival advantage in non-small-cell lung cancer. J. Clin. Oncol 23, 8959-8967 (2005).
18. Irani, A. A. et al. Two types of human mast cells that have distinct neutral protease compositions. Proc. Natl. Acad. Sci. USA 83, 4464-4468 (1986).
19. Bradding, P. et al. Heterogeneity of human mast cells based on cytokine content. J. Immunol. 155, 297-307 (1995).
20. Ibaraki, T. et al. The relationship of tryptase-and chymase-positive mast cells to angiogenesis in stage I non-small cell lung cancer. Eur. J Cardiothorac. Surg. 28, 617-621 (2005).
21. Bradding, P. et al. Interleukin-4,-5.,-6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 10, 471-480 (1994).
22. Bongartz, T. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-2285 (2006).
23. Stone, J. H. et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 54, 1608-1618 (2006).
24. Szlosarek, P. W., Balkwill, F. R. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 4, 565-573 (2003).
25. Ohri, C. M., Shikotra, A., Green, R. H., Waller, D. A., Bradding, P. Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer. BMC Cancer 10, 323 (2010).
26. Ohri, C. M., Shikotra, A., Green, R. H., Waller, D. A., Bradding, P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 33, 118-126 (2009).
27. Irani, A. M., Schwartz, L. B. Mast cell heterogeneity. Clin. Exp. Allergy 19, 143-155 (1989).
28. Esendagli, G. et al. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 59, 32-40 (2008).
29. Walsh, L. J. et al. Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proc. Natl. Acad. Sci. USA 88, 4220-4224 (1991).
30. Ohkawara, Y. et al. Human lung mast cells and pulmonary macrophages produce tumor necrosis factor-alpha in sensitized lung tissue after IgE receptor triggering. Am. J. Respir. Cell Mol. Biol. 7, 385-392 (1992).
31. Varadaradjalou, S. et al. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol 33, 899-906 (2003).
32. Bhattacharyya, S. P. et al. Activated T lymphocytes induce degranulation and cytokine production by human mast cells following cell-to-cell contact. J Leukoc. Biol 63, 337-341 (1998).
33. Nakae, S. et al. Mast cells enhance T cell activation: Importance of mast cell-derived TNF. Proc. Natl. Acad. Sci. USA 102, 6467-6472 (2005).
34. Nakae, S. et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 176, 2238-2248 (2006).
35. Voehringer, D. Protective and pathological roles of mast cells and basophils. Nat. Rev Immunol 13, 362-375 (2013).
36. Wolff, H. et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58, 4997-5001 (1998).
37. Huang, M., Sharma, S., Mao, J. T., Dubinett, S. M. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 157, 5512-5520 (1996).
38. Khuri, F. R. et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res. 7, 861-867 (2001).
39. Kay, L. J., Yeo, W. W., Peachell, P. T. Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation. Br J Pharmacol 147, 707-713 (2006).
40. Abdel-Majid, R. M., Marshall, J. S. Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J Immunol 172, 1227-1236 (2004).
41. Detoraki, A. et al. Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. J Allergy Clin Immunol 123, 1142-9, 1149 (2009).
42. Duffy, S. M., Cruse, G., Cockerill, S. L., Brightling, C. E., Bradding, P. Engagement of the EP2 prostanoid receptor closes the K+ channel KCa3. 1 in human lung mast cells and attenuates their migration. Eur J Immunol 38, 2548-2556 (2008).